Notice2022-12485
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 10, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 112 (Friday, June 10, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 112 (Friday, June 10, 2022)]
[Notices]
[Page 35559]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-12485]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Dawn Taylor-Mulneix at 301-767-5189,
or <a href="/cdn-cgi/l/email-protection#325653455c1c46534b5e5d401f5f475e5c575b4a725c5b5a1c555d44"><span class="__cf_email__" data-cfemail="ef8b8e9881c19b8e9683809dc2829a83818a8697af818687c1888099">[email protected]</span></a>. Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Human Monoclonal Antibodies That Broadly Target Coronaviruses
Description of Technology
The family of coronaviruses cause upper respiratory tract disease
in humans and have caused three major disease outbreaks in recent
history: the 2003 SARS outbreak, the 2012 MERS outbreak, and the
current SARS-CoV-2 pandemic. There is an urgent need for strategies
that broadly target coronaviruses, both to deal with new SARS-CoV-2
variants and future coronavirus outbreaks.
Scientists at NIAID have developed several novel human monoclonal
antibodies that bind to conserved parts of the SARS-CoV-2 spike
protein. These antibodies can neutralize SARS-CoV-2 variants of concern
including Omicron BA.1 and BA.2, as well as neutralize at least one
other betacoronavirus. Further, these antibodies limit disease in
animal models. Broadly reactive antibodies against coronaviruses are
useful tools to identify conserved sites on the coronavirus spike
protein, which could be investigated for the development of broad
coronavirus vaccines that aim to prevent future pandemics. Potent
neutralizers that target these sites could also be useful for
prevention of disease caused by diverse coronaviruses, including those
that may emerge in the future.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Prophylactic usage against SARS-CoV-2 and/or other
betacoronaviruses in normal or high-risk populations.
<bullet> Therapeutic treatment, alone or in combination, in
patients with SARS-CoV-2 and/or other betacoronaviruses infections.
<bullet> Assay development for surveillance, diagnostic, and
prevention measures.
Competitive Advantages
<bullet> Antibodies can neutralize SARS-CoV-2 variants, including
Omicron BA.1 and BA.2.
<bullet> Antibodies can broadly target and neutralize
betacoronaviruses.
Development Stage
<bullet> Pre-Clinical.
Inventors: Joshua Tan, Ph.D., Cherrelle Dacon, Ph.D., both of
NIAID.
Publications: Dacon, C., et al. ``Broadly neutralizing antibodies
target the coronavirus fusion peptide'' bioRxiv 2022.04.11.48789. Doi:
<a href="https://doi.org/10.1101/2022.04.11.48789">https://doi.org/10.1101/2022.04.11.48789</a> (This article is a preprint
and has not been certified by peer review)
Intellectual Property: HHS Reference No. E-047-2022-0-EIR-00 U.S.
Patent Application No. 63/308,898, filed on February 10, 2022.
Licensing Contact: To license this technology, please contact Dawn
Taylor-Mulneix at 301-767-5189, or <a href="/cdn-cgi/l/email-protection#4f2b2e3821613b2e3623203d62223a23212a26370f21262761282039"><span class="__cf_email__" data-cfemail="acc8cddbc282d8cdd5c0c3de81c1d9c0c2c9c5d4ecc2c5c482cbc3da">[email protected]</span></a>, and
reference E-047-2022.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. Areas of specific
interest include (a) testing developability of these antibodies (e.g.,
biophysical characteristics, cross-reactivity, pharmacokinetics,
toxicity), (b) pre-clinical model assessment, and (c) human clinical
trials. For collaboration opportunities, please contact Dawn Taylor-
Mulneix at 301-767-5189, or <a href="/cdn-cgi/l/email-protection#234742544d0d57425a4f4c510e4e564f4d464a5b634d4a4b0d444c55"><span class="__cf_email__" data-cfemail="e783869089c993869e8b8895ca8a928b89828e9fa7898e8fc9808891">[email protected]</span></a>.
Dated: June 3, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-12485 Filed 6-9-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 10, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.